logo-loader

BetterLife Pharma closes first tranche of non-brokered private placement for gross proceeds of $1,361,777

Published: 08:09 11 Aug 2020 EDT

BetterLife Pharma Inc -
Altum’s therapeutic pipeline consists of 3 products, including AP-003, a patent-pending interferon a2b (IFNa2b) inhalation formulation

BetterLife Pharma Inc. (CSE:BETR) (OTCQB:BETRF) (FRA:NPAT) said it has closed the first tranche of its non-brokered private placement by issuing 716,725 units at a price of $1.90 per unit for gross proceeds of $1,361,777.

Each unit consists of one common share in the company and one half of one common share purchase warrant. Each whole warrant is exercisable for a period of two years from the closing date of the offering to purchase one common share at a price of $2.30 each.

READ: BetterLife Pharma says special meeting of Altum shareholders has “overwhelming” voted to approve the planned merger

The common shares and warrants issued under the offering are subject to a hold period under applicable securities laws, which expires four months and a day following the date of issue of the units.

BetterLife said it will use the proceeds for working capital purposes and to advance on the AP-003 clinical trial programs of Altum Pharmaceuticals Inc, which are planned to begin in the next 6 to 10 weeks. 

As announced on July 30, 2020, 91.3% of Altum’s shareholders voted in favour of the merger with BetterLife and BetterLife now awaits ratification of the merger by the Canadian Securities Exchange.

Altum’s therapeutic pipeline consists of 3 products, including AP-003, a patent-pending interferon a2b (IFNa2b) inhalation formulation. Recent studies in China and the UK have provided data that suggest the therapeutic efficacy of interferon-based treatments for coronavirus (COVID-19).

Contact the author at jon.hopkins@proactiveinvestors.com

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

51 minutes ago